Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks.

Authors:
Deborah Moskowitz

Altern Med Rev 2006 Sep;11(3):208-23

Numerous forms of estrogens and progestins are utilized for the treatment of menopausal complaints and associated conditions that occur temporally. Although known to be different with respect to molecular structure, receptor affinity, metabolism, and other physiological traits, most have been treated as if they were clinically identical. The majority of these hormone preparations, commonly referred to as hormone replacement therapy (HRT), should perhaps be more aptly referred to as hormone substitution therapy, as most of the therapies utilized do not exactly match those produced in the body. Research indicates these synthetic hormones vary clinically in safety and efficacy. As such, women and their physicians have, in increasing numbers, been opting for the use of bioidentical hormones; i.e., those that match the structure and function of hormones produced in the body. With greater utilization and research surrounding bioidentical hormones, the differences can now begin to be fully assessed and appreciated. This article reviews the disparities between synthetic and bioidentical estrogens and progestins/progesterone with respect to safety and efficacy; special attention is devoted to clinical outcomes in the breast, endometrium, bone, cardiovascular system, and brain. The studies reviewed suggest bioidentical progesterone does not have a negative effect on blood lipids or vasculature as do many synthetic progestins, and may carry less risk with respect to breast cancer incidence. Studies of both bioidentical estrogens and progesterone suggest a reduced risk of blood clots compared to non-bioidentical preparations. Bioidentical hormone preparations have demonstrated effectiveness in addressing menopausal symptoms. The author advocates for continued research on bioidentical hormones and concludes there is currently sufficient evidence to support their preferred use over that of their synthetic cousins.

Download full-text PDF

Source
September 2006

Publication Analysis

Top Keywords

bioidentical hormones
16
safety efficacy
12
referred hormone
8
hormone preparations
8
bioidentical estrogens
8
bioidentical
8
produced body
8
hormones
6
disparities synthetic
4
synthetic bioidentical
4
reviews disparities
4
appreciated article
4
fully assessed
4
assessed appreciated
4
estrogens progestins/progesterone
4
article reviews
4
special attention
4
outcomes breast
4
breast endometrium
4
endometrium bone
4

Altmetric Statistics


Show full details
1 Total Shares
1 Wikipedia Pages
1 Citations

Similar Publications

Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.

Authors:
Chrisandra L Shufelt JoAnn E Manson

J Clin Endocrinol Metab 2021 Jan 28. Epub 2021 Jan 28.

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Context: This mini-review provides an overview of menopausal hormone therapy (HT) and cardiovascular disease (CVD) risk, with a focus on the role of hormone formulation, dose, and route of delivery.

Methods: This summary is based on authors' knowledge in the field of menopausal HT and supplemented by a PubMed search using the terms "menopause hormone therapy", "transdermal", "estradiol", "conjugated estrogens", "bioidentical", "cardiovascular disease", "lipoproteins", "glucose", "progestogens", "low dose".

Results: Available evidence indicates that oral unopposed estrogens have a favorable effect on lipoprotein levels, glycemia, insulin and CVD risk, however the addition of progestogens blunts the lipid-related effects. Read More

View Article and Full-Text PDF
January 2021
Similar Publications

Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 2.

Authors:
Angela DeRosa

Int J Pharm Compd 2021 Jan-Feb;25(1):14-17

Hormonal Health Institute, Scottsdale, Arizona.

This represents part two of a two-part article on the topic of gender bias within hormone replacement therapy and the well-orchestrated attempt by the pharmaceutical industry to eliminate bioidentical hormones, as well as to downplay the important role of compounding pharmacies in fulfilling the needs of women in this longstanding gender gap. Part one of this two-part article was published in the November/December 2020 issue of the International Journal of Pharmaceutical Compounding. That article discussed two of the four most prevalent reasons for this bias, Protecting the Bottom Line and Lack of Patent Protection. Read More

View Article and Full-Text PDF
January 2021
Similar Publications

Bioidentical hormones.

Authors:
F Z Stanczyk H Matharu S A Winer

Climacteric 2021 Feb 6;24(1):38-45. Epub 2021 Jan 6.

Departments of Obstetrics and Gynecology.

After the results of the Women's Health Initiative trials were published, patient and clinician interest in potential alternatives to conventional hormone therapy (HT) has grown. A commonly used alternative therapy involves custom-compounded steroid hormone preparations, formulated by compounding pharmacies. Many postmenopausal women consider the hormones as natural or bioidentical, in contrast to hormones used in conventional HT, which they consider synthetic. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause.

Authors:
C Brock Woodis Emily Ghassemi Amber N McLendon

Ann Pharmacother 2020 Dec 21:1060028020982611. Epub 2020 Dec 21.

Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA.

Objective: To review the efficacy, safety, and available literature regarding the novel combination bioidentical product Bijuva, or 17β-estradiol/progesterone (17β-E/P), for the treatment of moderate to severe menopausal symptoms in cisgender females with an intact uterus.

Data Sources: Literature searches of both PubMed (1966 to October 2020) and Google Scholar were conducted using search terms including , and .

Study Selection And Data Extraction: All articles with studies conducted in cisgender human females and in the English language were considered for review; 18 publications were included. Read More

View Article and Full-Text PDF
December 2020
Similar Publications

Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 1.

Authors:
Angela DeRosa

Int J Pharm Compd 2020 Nov-Dec;24(6):466-470

Hormonal Health Institute, Scottsdale, Arizona.

Gender bias within hormone replacement therapy has been prevalent for decades, and the circumstances surrounding this bias continue to worsen. A billion-dollar industry has been built on dozens of testosterone replacement therapies and medications to treat andropause and erectile dysfunction for men; women have been less fortunate. This article discusses this bias and the well-orchestrated attempt by the pharmaceutical industry to eliminate bioidentical hormones, as well as to downplay the important role of compounding pharmacies in fulfilling the needs of women in this longstanding gender gap. Read More

View Article and Full-Text PDF
November 2020
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap